Biogen dans l'actualité
Pionnier mondial des médicaments biotechnologiques
Tamtam a trouvé 20 articles récents sur Biogen.
- Biogen: Why I'm Still Bullish Despite Market Turmoil (NASDAQ:BIIB)
- Biogen (BIIB) PT Raised to $271 at Mizuho
- H.C. Wainwright reiterates Buy rating on Biogen stock at $270
- Eisai and Biogen Present Clarity AD Analysis Showing Lecanemab Slows Decline in Early Alzheimer’s Disease Patients With α-Synuclein Co-Pathology
- Biogen unblurs life with Friedreich ataxia in patient-centered Skyclarys campaign
- Can Biogen (NASDAQ:BIIB) Strengthen Lecanemab Case With Biomarker Data?
- Biogen says low dose of its experimental tau-reducing drug fares even better after nearly 2 years
- Eisai and Biogen Report Three-Year Real-World LEQEMBI Data Showing Slower Alzheimer’s Progression in LEADER Study
- Biogen to Participate in December Healthcare Conferences
- NICE initial recommendation not to approve tofersen
- Biogen reports two-year data for Alzheimer's drug diranersen
- Biogen: 3 Key Takeaways for Long-Term Investors
- Biogen (BIIB) Reports Promising Phase 2 CELIA Trial Results for Early Alzheimer's Therapy
- Diranersen shows 38% clinical decline slowing a...
- Biogen Prepares Joint Lupus Trial Results as It Targets First Revenue Growth Since 2019
- Biogen’s Diranersen Data Show Slower Alzheimer’s Decline Over Two Years
- Biogen reports positive two-year data for Alzheimer’s drug By Investing.com
- Biogen's anti-tau Alzheimer's drug benefits increase at 2 years
- Biogen releases new mid-stage data for early Alzheimer's asset diranersen
- The Rosen Law Firm, P.A. Announces Proposed Class Action
Articles collectés par Tamtam et retenus lorsqu'ils portent sur l'entreprise, des plus récents aux plus anciens. Chacun renvoie à sa source.
Vous vendez à des entreprises comme Biogen ?
Tamtam trouve les entreprises qui correspondent à votre client idéal, analyse chaque compte et vous dit qui contacter, et quand.
Trouver des entreprises similaires